In brief
This ClinicalTrials. gov record describes a recruiting RCT (NCT07209917) in India testing a nurse-led, ASHA co-delivered SAKHI HPV intervention to prevent HR-HPV persistence and cervical cancer in women with HIV/HR-HPV co-infection.
What this article is about
Quick Answer
This ClinicalTrials.gov record describes a recruiting RCT (NCT07209917) in India testing a nurse-led, ASHA co-delivered SAKHI HPV intervention to prevent HR-HPV persistence and cervical cancer in women with HIV/HR-HPV co-infection. It builds on prior success of an ASHA-Nutrition program improving immune function and psychosocial outcomes. The study aims to show if this refined multifaceted approach is more effective than enhanced standard care for reducing HPV-related risks.
Student takeaways
Key Takeaways
- The study aims to determine if a nurse-led, ASHA co-delivered SAKHI HPV intervention reduces HR-HPV persistence compared to an Enhanced Standard of Care (SOC+) program among 348 women with HIV/HPV co-infection in India.
- Previous research by the same team showed that their ASHA-Nutrition R01 intervention improved CD4+ T cell recovery, anthropometric outcomes, depression scores, ART adherence, social support, and reduced internalized stigma among rural WLH receiving emotional support, skill-building, nutrition education, and protein supplements.
- The primary outcome for the current trial is HR-HPV persistence (two positive tests for the same HR-HPV type separated by 12-18 months).
- Secondary outcomes include HIV viral load, CD4 count, and serum albumin levels at 6-, 12-, and 18-month intervals.
- The trial is a randomized controlled study (RCT) with participants individually randomized in a 1:1 ratio to either the SAKHI HPV intervention group or the SOC+ control group.
Student summary
Why This Research Matters
This article describes a clinical trial in India aimed at preventing cervical cancer (CC) among women co-infected with human papillomavirus (HPV) and human immunodeficiency virus (HIV). Cervical cancer is a significant health issue for Indian women, with high rates of diagnosis and preventable deaths. The primary cause of CC is HPV infection, particularly high-risk strains (HR-HPV), which can lead to precancerous lesions that may progress to invasive cancer.
The study focuses on a vulnerable population: women living with HIV (WLH) who also have an HR-HPV infection. These women are at higher risk for developing CC due to several factors. First, their immune systems, already compromised by HIV, are less able to fight off persistent HPV infections. Second, the article notes that WLH often face barriers such as lack of access to regular cervical screening (like Pap smears or HPV tests), high levels of depressive symptoms and stigma related to their conditions, and malnutrition.
Malnutrition is particularly concerning because it can negatively impact immune cell function. This means that even if a woman with HIV/HPV co-infection receives antiretroviral therapy (ART) for her HIV, poor nutrition might hinder the body's ability to control HPV infection effectively. The article also mentions that depressive symptoms in women living with HIV are linked to poorer health outcomes like lower viral suppression and potentially worse management of their overall condition.
The research team has previously conducted a study called ASHA-Nutrition R01, which involved training community health workers (Accredited Social Health Activists or ASHAs) to provide support to rural WLH. This earlier intervention included emotional support, skill-building, nutrition education, and protein-enriched food supplements. The results from this prior work were promising: participants showed improved CD4+ T cell recovery (a measure of immune strength), better anthropometric outcomes (like body measurements indicating health), reduced depression scores, improved ART adherence, increased social support, and decreased internalized stigma.
Building on these positive findings, the current study aims to develop a new intervention called SAKHI HPV. This program is designed specifically for women co-infected with HIV/HPV in India. It will be led by nurses but also involve ASHAs (community health workers) who have been trained as part of this project. The core idea is that providing comprehensive support, including nutritional guidance and education alongside psychological support, could help prevent the progression of HPV-related cervical lesions to cancer.
The study design involves a randomized controlled trial (RCT). This means 348 high-risk women with HIV/HPV co-infection will be recruited. They will then be randomly assigned in a 1:1 ratio to one of two groups: 1) The SAKHI HPV intervention group, which receives the new comprehensive program. 2) An Enhanced Standard of Care (SOC+) group, who receive usual care plus three additional sessions focused on wellness, basic nutrition education, and general health promotion related to HIV/HPV. The main goal is to see if women in the SAKHI HPV group have lower rates of persistent HR-HPV infection compared to those in the SOC+ group. Persistent HR-HPV infection (meaning two positive tests for the same high-risk type separated by 12-18 months) is a key risk factor for developing cervical cancer.
Secondary outcomes will also be measured, including changes in HIV viral load and CD4 count (to assess overall HIV health), and nutritional status using serum albumin levels. The study aims to recruit participants who are already engaged in the HIV treatment cascade, meaning they are receiving ART, but it's important that their nutritional health is managed as part of this intervention.
For nursing students, understanding this research highlights several key points: The article clearly frames a significant public health problem: cervical cancer among women with HIV/HPV co-infection. It identifies multiple risk factors beyond just the infections themselves (like poor screening access, mental health issues like depression and stigma, and malnutrition). This shows that nursing care for such patients needs to be holistic. Students should appraise how this study builds upon previous research (the ASHA-Nutrition R01 trial) by refining an intervention. The use of a randomized controlled trial is a strong methodological approach to test the efficacy of the new program compared to enhanced standard care. It's important for students to understand what constitutes 'standard of care' in this context and how the SAKHI HPV program aims to improve upon it. Regarding source/rights cautions, the information comes from ClinicalTrials.gov (NCT07209917), which is a public registry. The copyright notice indicates that these are metadata for the trial registration itself. While this provides valuable details about the study's design and aims, students should be aware that full published results or detailed methodologies might not yet be available from ClinicalTrials.gov alone; they would typically come from peer-reviewed journal articles once the research is completed. A nurse reasoning from this evidence (once it becomes available) could consider how to integrate comprehensive support services into their practice for similar patient populations. If the SAKHI HPV intervention proves effective, nurses might advocate for or help implement such programs in community settings, particularly focusing on education about cervical cancer screening, nutritional counseling, and addressing psychosocial needs like depression and stigma among women living with HIV/HPV co-infection.
Source abstract
Study Overview
Cervical cancer (CC) remains one of the most common malignancies among women in India, with nearly 100,000 women diagnosed annually and over 60,000 preventable deaths annually. With high-risk human papillomavirus (HR-HPV) as the causative agent for CC, one risk factor that places women at high risk for CC is human immunodeficiency virus (HIV), as impaired immune response against Human papillomavirus (HPV) may result in persistent HR-HPV infection, a critical risk factor for progression of HPV-related cervical oncogenesis. Progression of precancerous lesions among women living with HIV (WLH) is also associated with: 1) lack of HPV screening; 2) high levels of depressive symptoms and stigma; and 3) malnutrition, which negatively impacts the activation and proliferation of immune cells. Yet programs that offer WLH with comprehensive services focused on HPV screening and psychological and nutritional support are almost non-existent, and the gap is critical. Nutrition plays an integral role in relationship to HPV/HIV co-infection, as demonstrated by an increased risk of HR-HPV associated with poor nutrition; nutritional deficiencies are likewise linked to cervical intra-epithelial neoplasia. The immunological effect of malnutrition may also be exacerbated among WLH due to elevated energy demands of chronic immune activation; worsened with HPV/HIV co-infection. Further, depressive symptoms (aka depression for brevity) partially mediate the effect of food insecurity on HIV viral suppression. In our completed ASHA-Nutrition R01 study of antiretroviral (ART) adherence, the investigators trained lay community health workers, named Accredited Social Health Activist (ASHA), to improve the health of 600 rural WLH by providing emotional support, skill-building, nutrition education, and/or protein-enriched food supplements. In that study, our intervention, co-delivered by our trained ASHA, and guided by nurses, led to increased CD4+ T cell recovery and improved anthropometric and psychosocial outcomes. The investigators found that ASHA support plus protein supplements and nutritional education were significantly associated with improved CD4 counts and increased lean mass at 18 months (P \< 0.001), as well as significant improvements in depression, ART adherence, social support and internalized stigma. In our sub study, CC screening of 598 of these WLH revealed that 13% were found to have abnormal cervical lesions and 4 (1%) had squamous CC. Preliminary evidence also revealed that nutritional supplements may be associated with a 40% reduction in the risk of abnormal cervical lesions (adjusted odds ratio \[aOR\] = 0.60), with an association between serum albumin and reduced risk of abnormal lesions (aOR= 0.39).
With a focus on secondary prevention of CC, the investigators hope to mitigate the link between HR-HPV persistence and risk of CC as well as improve the health of women co-infected with HPV/HIV (W-Co-V). Our stellar team plans to build upon our prior ASHA-Nutrition intervention, using formative research to refine a nurse-led, ASHA co-delivered, nutrition-enhanced SAKHI HPV intervention, adapted for W-Co-V. This will be followed by a randomized controlled trial (RCT), assessing the efficacy of our refined comprehensive, multifaceted SAKHI HPV intervention, as compared with an enhanced Standard of Care (SOC+) (usual care + 3 sessions \[wellness, basic nutrition and HPV/HIV health promotion\]) among 348 high-risk co-infected women to prevent CC while remaining engaged in the HIV treatment cascade, and managing nutritional health. Recruited participants will be individually randomized in a 1:1 ratio into the two study arms. Our Primary outcome is HR-HPV persistence (2 positive tests for the same HR-HPV type, separated by 12-18 months). The two aims incorporating RCT interventions are as follows:
Aim 2. To evaluate the efficacy of SAKHI HPV intervention among 348 W-Co-V on the primary outcome (HR-HPV persistence) as compared to the Enhanced Standard of Care (SOC+) program. H2: Compared to the SOC+ participants, SAKHI participants will have lower rates of HR-HPV persistence.
Aim 3. Assess the impact of the SAKHI program secondarily on: 1) HIV indices (HIV viral load; CD4 count); 2) Nutritional index (serum albumin) at 6-, 12-, and 18-months.
Evidence appraisal
Main Findings
- The study aims to determine if a nurse-led, ASHA co-delivered SAKHI HPV intervention reduces HR-HPV persistence compared to an Enhanced Standard of Care (SOC+) program among 348 women with HIV/HPV co-infection in India.
- Previous research by the same team showed that their ASHA-Nutrition R01 intervention improved CD4+ T cell recovery, anthropometric outcomes, depression scores, ART adherence, social support, and reduced internalized stigma among rural WLH receiving emotional support, skill-building, nutrition education, and protein supplements.
- The primary outcome for the current trial is HR-HPV persistence (two positive tests for the same HR-HPV type separated by 12-18 months).
- Secondary outcomes include HIV viral load, CD4 count, and serum albumin levels at 6-, 12-, and 18-month intervals.
- The trial is a randomized controlled study (RCT) with participants individually randomized in a 1:1 ratio to either the SAKHI HPV intervention group or the SOC+ control group.
Practice transfer
Clinical Relevance
- If successful, the SAKHI HPV program could provide an evidence-based model for integrating comprehensive psychosocial and nutritional support into HIV care pathways to reduce cervical cancer risk in co-infected women.
- The findings may highlight the critical role of community health workers (ASHAs) trained by nurses in delivering multifaceted interventions that address both infectious disease management and broader determinants of health like nutrition and mental well-being.
- Positive results could lead to policy changes advocating for enhanced screening, education, and support services specifically tailored for women living with HIV/HPV co-infection in resource-limited settings such as India.
- The study underscores the importance of addressing malnutrition and its impact on immune function (CD4 counts) and HPV persistence, suggesting nutritional interventions could be a key component of cervical cancer prevention strategies for this population.
- Demonstrating efficacy would support further research into similar nurse-led community-based models for preventing other HPV-related cancers or managing chronic conditions in vulnerable populations.
Faculty notes
Educational Relevance
This ClinicalTrials.gov record (NCT07209917) outlines a significant randomized controlled trial (RCT) in India targeting secondary cervical cancer prevention for women co-infected with human papillomavirus (HR-HPV) and human immunodeficiency virus (HIV). The study, led by researchers from the University of California, Irvine, addresses a critical public health issue: cervical cancer remains one of the most common malignancies among Indian women, with high annual diagnosis rates (~100,000 cases) and preventable deaths exceeding 60,000. HR-HPV is the primary etiological agent for CC, and HIV co-infection substantially elevates this risk due to impaired immune response against HPV, leading to persistent infections that can progress to cervical oncogenesis.
The research builds upon a prior successful intervention (ASHA-Nutrition R01 study), which demonstrated that training Accredited Social Health Activists (ASHAs) – lay community health workers – to provide emotional support, skill-building, nutrition education, and protein-enriched food supplements significantly improved CD4+ T cell recovery, anthropometric outcomes, depression scores, ART adherence, social support, and reduced internalized stigma among 600 rural WLH. This foundational work highlights the potential of community-based interventions in improving health outcomes for this vulnerable population.
The current study aims to develop and evaluate a refined, nurse-led intervention called SAKHI HPV (co-delivered by trained ASHAs) specifically adapted for women co-infected with HIV/HPV (W-Co-V). The primary objective is to assess the efficacy of this comprehensive, multifaceted program in reducing HR-HPV persistence compared to an Enhanced Standard of Care (SOC+) group. SOC+ involves usual care plus three sessions on wellness, basic nutrition, and HPV/HIV health promotion.
Key aspects include: The study population consists of 348 high-risk W-Co-V women recruited from India. Participants will be individually randomized in a 1:1 ratio to either the SAKHI HPV intervention group or the SOC+ control group. The primary outcome is HR-HPV persistence, defined as two positive tests for the same HR-HPV type separated by 12-18 months. Secondary outcomes include HIV indices (viral load, CD4 count) and nutritional status (serum albumin), assessed at 6-, 12-, and 18-month intervals.
This trial is crucial as it directly addresses the gap in comprehensive services for WLH with HR-HPV co-infection. It investigates how integrated support – encompassing psychological, nutritional, and educational components delivered by nurses and community health workers – can mitigate cervical cancer risk while also improving overall HIV management and nutritional health. The findings could inform public health strategies and clinical practice guidelines for managing this high-risk group in resource-limited settings like India.
Critical appraisal
Limitations
- The study is currently recruiting (as per the 'RECRUITING' status), so final results and definitive conclusions are not yet available.
- Generalizability of findings might be limited if the recruited sample does not fully represent all women with HIV/HPV co-infection in India or other similar settings.
- The effectiveness of the intervention relies heavily on the training, fidelity, and engagement of both nurses (leading) and ASHAs (co-delivering), which can vary in practice.
Classroom use
Discussion Questions
- How might the integration of nutritional support and psychological counseling within HIV care programs impact long-term health outcomes for women with co-infections?
- What are the potential challenges in scaling up a nurse-led, ASHA co-delivered intervention like SAKHI HPV across different regions or healthcare systems in India?
- Considering the high rates of cervical cancer preventable deaths in India, what role can community-based interventions play alongside traditional medical treatments and screening programs?
- How do factors like stigma and depression specifically identified as barriers for WLH with HR-HPV co-infection influence adherence to comprehensive prevention programs?
- What ethical considerations arise when conducting research involving vulnerable populations such as women living with HIV/HPV, especially in resource-limited settings?
- If the SAKHI HPV intervention proves effective, how could its components be adapted for other chronic conditions or health promotion efforts targeting similar high-risk groups?
- How does this study's focus on secondary prevention (reducing HR-HPV persistence) complement primary prevention strategies like HPV vaccination in managing cervical cancer risk among WLH with co-infections?
- What are the potential cost-effectiveness implications of implementing a comprehensive intervention like SAKHI HPV compared to standard care or other existing programs for this population?
- How can findings from such trials be effectively translated into policy and practice guidelines within national health systems, particularly in low- and middle-income countries?
- What further research is needed after the completion of this trial to fully understand the long-term impact on cervical cancer incidence and mortality among women who participated?
Search-ready answers
Frequently asked questions
What is the primary goal of this clinical trial regarding cervical cancer prevention in women co-infected with HPV and HIV?
The primary goal, as stated in Aim 2, is to evaluate the efficacy of a nurse-led, ASHA co-delivered, nutrition-enhanced SAKHI HPV intervention among high-risk co-infected women on preventing HR-HPV persistence (defined as two positive tests for the same HR-HPV type separated by 12-18 months), compared to an Enhanced Standard of Care (SOC+) program.
What is the main outcome measure being assessed in this study?
The primary outcome measure being assessed is HR-HPV persistence, defined as two positive tests for the same high-risk human papillomavirus type separated by 12-18 months.
Who are the target participants for this clinical trial?
The target participants are women co-infected with Human Papillomavirus (HPV) and Human Immunodeficiency Virus (HIV), specifically those who are at high risk for cervical cancer. The study plans to recruit 348 such women.
What is the SAKHI HPV intervention, and how does it relate to previous research?
The SAKHI HPV intervention is a nurse-led program co-delivered by Accredited Social Health Activists (ASHA). It builds upon prior ASHA-Nutrition R01 study findings where similar interventions improved CD4+ T cell recovery, anthropometric outcomes, and psychosocial well-being in women living with HIV. The SAKHI HPV intervention is specifically adapted for women co-infected with HPV/HIV.
What are the two main arms of this randomized controlled trial?
The study involves a 1:1 randomization into two arms: one receiving the refined comprehensive, multifaceted SAKHI HPV intervention and the other receiving an Enhanced Standard of Care (SOC+) program. SOC+ consists of usual care plus three sessions on wellness, basic nutrition, and HPV/HIV health promotion.
What are some key risk factors for cervical cancer progression mentioned in the study's background?
Key risk factors highlighted include: 1) lack of HPV screening; 2) high levels of depressive symptoms and stigma; and 3) malnutrition. These factors negatively impact immune response against HR-HPV, leading to persistent infection and progression of precancerous lesions.
What preliminary evidence is mentioned regarding the potential benefits of nutritional supplements?
Preliminary evidence from a sub-study involving CC screening revealed that nutritional supplements may be associated with a 40% reduction in the risk of abnormal cervical lesions (adjusted odds ratio [aOR] = 0.60). An association was also noted between serum albumin and reduced risk of abnormal lesions (aOR= 0.39).
What is the role of Accredited Social Health Activists (ASHA) in this intervention?
Accredited Social Health Activists (ASHAs), who are lay community health workers, play a crucial role as co-delivers of the SAKHI HPV intervention. They provide emotional support, skill-building, nutrition education, and/or protein-enriched food supplements to participants.
What is the study's focus concerning secondary prevention?
The study focuses on secondary prevention of cervical cancer by aiming to mitigate the link between HR-HPV persistence and risk of cervical cancer (CC), while also improving the overall health of women co-infected with HPV/HIV (W-Co-V).
What are some of the secondary outcomes being assessed in this trial?
Secondary outcomes include: 1) HIV indices such as viral load and CD4 count; and 2) Nutritional index, specifically serum albumin levels, all measured at 6-, 12-, and 18-month intervals.